Related Experiment Video
Updated: Aug 7, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Written action plans for asthma in children
Insights
Symptom-based written asthma action plans (WAP) reduce acute care visits in children. Peak flow monitoring in WAPs showed fewer symptomatic days, but symptom monitoring was preferred by children.
Area of Science:
- Pediatric Pulmonology
- Asthma Management
- Clinical Trials
Background:
- Written asthma action plans (WAP) are recommended for asthma management.
- Limited trials isolate the effect of WAP versus no WAP.
Purpose of the Study:
- Evaluate the independent effect of WAP in children and adolescents with asthma.
- Compare different types of WAP.
Main Methods:
- Systematic review of randomized controlled trials (RCTs).
- Searched Cochrane Airways Group Specialised Register, MEDLINE, EMBASE, CINAHL.
- Included trials comparing WAP with no WAP or different WAP.
Main Results:
- Symptom-based WAP reduced acute care visits (RR 0.73).
- Number needed to treat for symptom-based WAP was 9.
- Children preferred symptom monitoring over peak flow monitoring.
Conclusions:
- Symptom-based WAP appear superior to peak flow WAP for preventing acute care visits.
- Further research needed to confirm reasons for superiority.
Background:
While all asthma consensus statements recommend the use of written action plan (WAP) as a central part of asthma management, a recent systematic review of randomised trials highlighted the paucity of trials where the only difference between groups was the provision or not of a written action plan.
Objectives:
The objectives of this review were firstly to evaluate the independent effect of providing versus not providing a written action plan in children and adolescents with asthma, and secondly to compare the effect of different written action plans.
Search Strategy:
We searched the Cochrane Airways Group Specialised Register (November 2004), which is derived from searches of CENTRAL, MEDLINE, EMBASE, CINAHL, as well as handsearched respiratory journals, and meeting abstracts. We also searched bibliographies of included studies and identified review articles.
Selection Criteria:
Randomised controlled trials were included if they compared a written action plan with no written action plan, or different written action plans with each other.
Data Collection And Analysis:
Two authors independently selected the trials, assessed trial quality and extracted the data. Study authors were contacted for additional information.
Main Results:
Four trials (three RCTs and one quasi-RCT) involving 355 children were included. Children using symptom-based WAPs had lower risk of exacerbations which required an acute care visit (N = 5; RR 0.73; 95% CI 0.55 to 0.99). The number needed to treat to prevent one acute care visit was 9 (95% CI 5 to 138). Symptom monitoring was preferred over peak flow monitoring by children (N = 2; RR 1.21; 95% CI 1.00 to 1.46), but parents showed no preference (N = 2; RR 0.96; 95% CI 0.18 to 2.11). Children assigned to peak flow-based action plans reduced by 1/2 day the number of symptomatic days per week (N = 2; mean difference: 0.45 days/week; 95% CI 0.04 to 0.26). There were no significant group differences in the rate of exacerbation requiring oral steroids or admission, school absenteeism, lung function, symptom score, quality of life, and withdrawals.
Authors' Conclusions:
The evidence suggests that symptom-based WAP are superior to peak flow WAP for preventing acute care visits although there is insufficient data to firmly conclude whether the observed superiority is conferred by greater adherence to the monitoring strategy, earlier identification of onset of deteriorations, higher threshold for presentation to acute care settings, or the specific treatment recommendations.
Related Concept Videos
Asthma-IV: Nursing Management
First, in...
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma-I: Introduction
Inhaled Medications
Asthma-III: Symptoms and Complications
Classification of Asthma
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...